3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 2/3
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
5
Other hematologic neoplasm
2
Gastrointestinal
2
Thoracic
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Conditions
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoproliferative Disorders
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
26
Rituximab
17
Etoposide
16
Methotrexate
15
Dexamethasone
15
Cytarabine
15
Vincristine
14
Prednisone
11
Doxorubicin
11
Radiotherapy
10
blinatumomab
8
fludarabine
7
Mercaptopurine
7
Filgrastim
7
Daunorubicin
7
Asparaginase
7
pegaspargase
6
Granulocyte Colony-Stimulating Factor
6
Methylprednisolone
5
Drug Therapy
5
Dasatinib
5
venetoclax
4
prednylidene
4
etoposide phosphate
4
deltacortene
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Magnetic Resonance Spectroscopy
4
Gemcitabine
4
Busulfan
4
Bendamustine Hydrochloride
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
pertuzumab
×
Lymphoid
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled